L
2.58
0.04 (1.57%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Larimar Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -4.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | -0.3 |
| AI Insight | NA |
| Weighted Average | 0.31 |
Select this tab to load the latest available analysis.
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.43% |
| % Held by Institutions | 103.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 9,163,157 |
| Defilade Capital Management, L.P. | 30 Jun 2026 | 3,670,135 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |